PROGRAM CHAIR
Julia K. Rotow, MD
Medical Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA
FACULTY PRESENTER
Shayma Kazmi, MD
Medical Oncologist
Penn Medicine
Cherry Hill, NJ
PROGRAM OVERVIEW
This program will discuss tumorigenesis in advanced non-small cell lung cancer (NSCLC) and the mechanism of actions of checkpoint inhibitors, the latest clinical data describing the efficacy and safety of first-line use of PD-1 inhibitor therapy, alone and in combination, and the use of immunotherapy in the first-line treatment of NSCLC with no actionable mutations.
TARGET AUDIENCE
This activity is designed to meet the educational needs of medical oncologists, oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to maintain an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies in the Department of Veteran Affairs.
EDUCATIONAL OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the effects that immune checkpoint inhibitors have on the pathophysiology of NSCLC
- Evaluate recent immunotherapy clinical trials data in the first-line treatment of patients with advanced NSCLC
- Explain the application of clinical practice guidelines in the management of Veterans with advanced NSCLC with no targetable mutations
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with NSCLC.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Julia K. Rotow, MD, reports that she has received consulting fees from AstraZeneca, AbbVie, Gritstone, Lilly, Takeda Pharmaceuticals and Sanofi-Genzyme. She has also been contracted for research (Principal Investigator – active or pending) from AstraZeneca, Blueprint, EpimAb, BioAtla, Bicycle Therapeutics, AbbVie, and Lilly, and has received honoraria/other royalties from AstraZeneca, Pfizer, Merck, Janssen, Sanofi-Genzyme, Lilly and Jazz.
Shayma Kazmi, MD, reports that she is a consultant for Foundation Medicine.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, MD, Medical Director for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASE DATE: October 07, 2022
EXPIRATION DATE: October 07, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
